Thromboelastogram in Postdelivery Preeclamptic Patients

Effect of Age on Reference Values for Thromboelastography in Pregnant Women With Pre-eclampsia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03555630

Enrollment

Registered

2018-06-13

Start date

2018-05-22

Completion date

2019-12-31

Last updated

2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coagulation Disorder, Preeclampsia, Pregnancy Complications

Brief summary

There are no studies evaluating the effect of aging on hemostasis of preeclamptic patients. Additionally, although there are some studies that establish normal reference values for TEG profiles in healthy term pregnant patients, conflicting results have been found in preeclampsia. Reference values are important to establish baseline parameters in cases of pre-eclampsia complicated by postpartum hemorrhage. The investigators will evaluate reference values for TEG in postdelivery preeclamptic patients and the difference between vaginal delivery and cesarean section.

Detailed description

After approval by the Institutional Review Board and informed consent from participants, the investigators are obtaining blood samples for TEG processing, from pregnant patients admitted to the maternity unit of Augusta University Medical Center. Patients are being classified in 2 groups: term pregnant patients with diagnosis of pre-eclampsia who undergo cesarean section and those having spontaneous vaginal delivery. Each group will be divided into subgroups according to maternal age: 18-25 years, 26-35 years, \>36 years. Pre-eclampsia is defined and classified according to the definitions of the American College of Obstetricians and Gynecologists published in 2013.

Interventions

DIAGNOSTIC_TESTThromboelastogram

Blood sample processing for thromboelastogram

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \> 18 years Mental competence Gestational age \> 37-week Informed consent Diagnosis of preeclampsia (with or without features of severity)

Exclusion criteria

Gestational age \< 37-week Known bleeding or thrombotic diathesis Use of aspirin or unfractionated or low-molecular weight heparin within the last 48 hours BMI \> 35 Maternal comorbid conditions other than preeclampsia

Design outcomes

Primary

Measure	Time frame	Description
R time	10 minutes	Reaction time of whole blood

Secondary

Measure	Time frame	Description
K time	10 minutes	Activation time
Maximum amplitude	10 minutes	Amplitude in relation to platelet count and function
LY-30	30 minutes	Lysis at 30 minutes

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026